K. Tutsch

I. Blair, P. Carbone, A. Verma, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Randomized Phase I Chemoprevention Dose-Seeking Study of α-Difluoromethylornithine

G. Wilding, R. Love, P. Carbone, 1993 .

Phase I trial of perillyl alcohol administered four times daily continuously

G. Wilding, M. Gould, H. Bailey, 2003, Cancer Chemotherapy and Pharmacology.

Phase I trial of perillyl alcohol administered

G. Wilding, M. Gould, H. Bailey, 2003 .

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.

J. Berlin, G. Wilding, K. Tutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

G. Wilding, J. Cleary, H. Bailey, 2002, Cancer Chemotherapy and Pharmacology.

Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

J. Berlin, G. Wilding, K. Tutsch, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of a Micronized Formulation of Carboxyamidotriazole , a Calcium Signal Transduction Inhibitor : Toxicity , Bioavailability and the Effect of Food 1

J. Berlin, G. Wilding, K. Tutsch, 2002 .

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

G. Wilding, D. Spriggs, R. Mulcahy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion.

J. Willson, J. Grem, D. Trump, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial and pharmacokinetics of carboplatin (nsc 241240) by single monthly 30‐minute infusion

J. Koeller, D. Trump, D. Tormey, 1986, Cancer.

Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat.

R. Wheeler, R. Earhart, K. Tutsch, 1983, Cancer research.

Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.

G. Wilding, D. Spriggs, D. Rushing, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

J. Cohen, H. Robins, K. Tutsch, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inadvertent administration of 480 mg/m2 of cisplatin.

J. Schiller, D. Trump, K. Tutsch, 1989, The American journal of medicine.

Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.

G. Wilding, R. Love, P. Carbone, 1993, Journal of the National Cancer Institute.

Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.

G. Wilding, A. Cheng, P. Hutson, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

G. Wilding, K. Tutsch, R. Arzoomanian, 2004, Investigational New Drugs.

Phase I trial of hepatic artery infusion of 5-iodo-2'-deoxyuridine and 5-fluorouracil in patients with advanced hepatic malignancy: biochemically based combination chemotherapy.

J. Willson, A. Benson, S. Remick, 1989, Cancer research.

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions

G. Wilding, J. Grem, D. Spriggs, 1992, Cancer Chemotherapy and Pharmacology.

Bioavailability Study of Oral Liquid and Tablet Forms of α-Difluoromethylornithine

P. Carbone, K. Tutsch, James P. Thomas, 2000 .

A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.

R. Love, K. Tutsch, A. Verma, 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days

G. Wilding, R. Hohl, S. Holstein, 2004, Cancer Chemotherapy and Pharmacology.

Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

J. Willson, J. Grem, D. Trump, 1987, Cancer treatment reports.

Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.

J. Koeller, D. Trump, D. Tormey, 1985, Cancer research.

Biochemical assessment of the effects of acivicin and dipyridamole given as a continuous 72-hour intravenous infusion.

J. Willson, C. Risueño, D. Trump, 1988, Cancer research.

Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.

J. Koeller, J. Willson, D. Trump, 1988, Cancer research.

Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients

D. Alberts, H. Garewal, A. Buzaid, 2004, Cancer Chemotherapy and Pharmacology.

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion1

G. Wilding, K. Tutsch, R. Arzoomanian, 2006 .

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion 1

G. Wilding, H. Bailey, K. Tutsch, 2006 .

Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.

M. Lindstrom, G. Wilding, C. Mcginn, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.

M. Mehta, B. Badie, G. Wilding, 2004, International journal of radiation oncology, biology, physics.

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

D. Mahvi, G. Wilding, R. Mulcahy, 1997, Journal of the National Cancer Institute.

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.

J. Berlin, G. Wilding, J. Cleary, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of vinblastine in combination with acrivastine in patients with advanced renal cell carcinoma

A. C. King, J. W. Findlay, J. Berlin, 2004, Investigational New Drugs.

Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.

E. Hawk, G. Kelloff, R. Lubet, 2000, Cancer research.

Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam.

G. Kelloff, A. Moser, R. Lubet, 1996, Cancer research.

Lack of thermal enhancement for taxanes in vitro.

J. Haveman, R. Rietbroek, D. Katschinski, 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.

Andreas Friedl, G. Wilding, A. Friedl, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

J. Schiller, D. Spriggs, K. Tutsch, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

G. Wilding, M. Gould, H. Bailey, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day 1

G. Wilding, M. Gould, H. Bailey, 2000 .

Phase I clinical trial of perillyl alcohol administered daily.

G. Wilding, M. Gould, J. Stewart, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

R. Love, J. Stewart, S. Attia, 2008, Cancer Chemotherapy and Pharmacology.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

D. DeMets, G. Wilding, H. Bailey, 2003, Investigational New Drugs.

Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies

J. Schiller, D. Spriggs, K. Tutsch, 1993, Investigational New Drugs.

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812)

G. Wilding, D. Spriggs, H. Robins, 2004, Investigational New Drugs.

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

G. Wilding, H. Bailey, K. Tutsch, 1991, Cancer research.

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

G. Wilding, D. Trump, R. Mulcahy, 1991, Cancer research.

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

G. Wilding, J. Kolesar, K. Tutsch, 2004, Clinical Cancer Research.

Phase I clinical and pharmacokinetic trial of irofulven

G. Wilding, H. Bailey, K. Tutsch, 2001, Cancer Chemotherapy and Pharmacology.

Evidence of an absorption phase after short intravenous suramin infusions

M. Christian, G. Wilding, P. Hutson, 2004, Cancer Chemotherapy and Pharmacology.

Phase I Chemoprevention Study of Piroxicam and rn

I. Blair, P. Carbone, A. Verma, 1998 .

Low-dose difluoromethylornithine and polyamine levels in human prostate tissue.

E. Messing, G. Wilding, R. Love, 1999, Journal of the National Cancer Institute.

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

J. Willson, M. Egorin, D. Trump, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

G. Wilding, J. Kolesar, W. See, 2013, The Prostate.

Methotrexate and dipyridamole combination chemotherapy based upon inhibition of nucleoside salvage in humans.

J. Willson, J. Grem, D. Trump, 1989, Cancer research.

Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.

P. Carbone, A. Verma, J. Pirsch, 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.

M. Mehta, G. Wilding, J. Cohen, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I T rial o f I ntravenous T hymidine a nd C arboplatin in P atients W ith A dvanced C ancer

M. Mehta, G. Wilding, E. Jacobson, 1999 .

1041 Leucovorin (LV) modulation of iododeoxyuridine (IdUrd) radiosensitization; A phase I study

C. Mcginn, K. Kunugi, T. Kinsella, 1995 .